{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:14:19Z","timestamp":1762841659472,"version":"build-2065373602"},"reference-count":61,"publisher":"IOP Publishing","issue":"6","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/publishingsupport.iopscience.iop.org\/iop-standard\/v1"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/iopscience.iop.org\/info\/page\/text-and-data-mining"}],"funder":[{"name":"Development Program \"Priority 2030\"","award":["IZ-023-202-2024"],"award-info":[{"award-number":["IZ-023-202-2024"]}]}],"content-domain":{"domain":["iopscience.iop.org"],"crossmark-restriction":false},"short-container-title":["Biomed. Phys. Eng. Express"],"published-print":{"date-parts":[[2025,11,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:italic>Objective.<\/jats:italic>\n                    Nowadays the linear-quadratic model (LQ) is the most used model to estimate the biological effective dose (BED) and the equivalent dose in 2 Gy fractions (\n                    <jats:italic>\n                      EQD\n                      <jats:sub>2<\/jats:sub>\n                    <\/jats:italic>\n                    ) for different fractionation regimens. Nevertheless, it is debated of applicability to use LQ model for hypofractionation. The objective of this study is to evaluate the LQ model in comparison with other radiobiological models concerning the adequacy of biological equivalent dose in 2 Gy fractions assessment across various hypofractionation regimens.\n                    <jats:italic>Methods.<\/jats:italic>\n                    The study was conducted for two cases: the prostate gland in the pelvic region and squamous cell carcinoma (SCC) in the head and neck region. Five radiobiological models including the LQ model, modified linear-quadratic (MLQ), linear-quadratic-linear (LQL), universal survival curve (USC), and Pade linear-quadratic (PLQ) models were compared for tumor control probability (\n                    <jats:italic>TCP<\/jats:italic>\n                    ) and\n                    <jats:italic>\n                      EQD\n                      <jats:sub>2<\/jats:sub>\n                    <\/jats:italic>\n                    predictions. Published clinical outcomes (including local control, disease-free survival, and overall survival rates) were analyzed to identify clinically equivalent fractionation regimens. The radiobiological models were then evaluated by comparing calculated\n                    <jats:italic>\n                      EQD\n                      <jats:sub>2<\/jats:sub>\n                    <\/jats:italic>\n                    and\n                    <jats:italic>TCP<\/jats:italic>\n                    values with clinical data for these equivalent regimens.\n                    <jats:italic>Results:<\/jats:italic>\n                    Modified radiobiological models showed that the LQ model overestimates the dose in hypofractionation. The dose limit at which the LQ model is applicable depends on the localization and type of tumor: for the prostate gland the value was 4.3 Gy, for the head and neck region 8.5 Gy.\n                    <jats:italic>Conclusions:<\/jats:italic>\n                    The applicability of the LQ model in hypofractionation depends on the tumor\n                    <jats:italic>\u03b1<\/jats:italic>\n                    \/\n                    <jats:italic>\u03b2<\/jats:italic>\n                    value: the LQ model more sensitive to locations with low\n                    <jats:italic>\u03b1<\/jats:italic>\n                    \/\n                    <jats:italic>\u03b2<\/jats:italic>\n                    values and, conversely, less sensitive to locations with high\n                    <jats:italic>\u03b1<\/jats:italic>\n                    \/\n                    <jats:italic>\u03b2<\/jats:italic>\n                    values. Among the alternatives, the MLQ model is recognized as the most practical alternative, combining a small number of parameters with resistance to variations. While modified models show efficacy, further clinical validation is needed to balance tumor control with normal tissue toxicity risks.\n                  <\/jats:p>","DOI":"10.1088\/2057-1976\/ae1039","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T22:47:42Z","timestamp":1759877262000},"page":"065043","update-policy":"https:\/\/doi.org\/10.1088\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Unveiling the impact of modified cell death models on hypofractionated radiation therapy efficacy"],"prefix":"10.1088","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1117-0649","authenticated-orcid":true,"given":"I R","family":"Sagov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0927-4559","authenticated-orcid":true,"given":"A A","family":"Sorokina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8251-2138","authenticated-orcid":false,"given":"E S","family":"Sukhikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0257-6017","authenticated-orcid":false,"given":"EA","family":"Selikhova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9583-5187","authenticated-orcid":false,"given":"Yu S","family":"Kirpichev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"266","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"bpexae1039bib1","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/s0140-6736(21)00233-6","type":"journal-article","article-title":"Contemporary radiotherapy: present and future","volume":"398","author":"Chandra","year":"2021","journal-title":"Lancet"},{"key":"bpexae1039bib2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijrobp.2020.10.039","type":"journal-article","article-title":"High dose per fraction, hypofractionated treatment effects in the clinic (HyTEC): an overview","volume":"110","author":"Grimm","year":"2021","journal-title":"International Journal of Radiation OncologyBiologyPhysics"},{"key":"bpexae1039bib3","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10527-024-10433-9","type":"journal-article","article-title":"Application of integral radiobiological criteria for qualitative comparison of remote radiotherapy technologies in the treatment of prostate tumors","volume":"58","author":"Sutygina","year":"2025","journal-title":"Biomed. Eng."},{"key":"bpexae1039bib4","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.semradonc.2008.04.005","type":"journal-article","article-title":"The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery","volume":"18","author":"Kirkpatrick","year":"2008","journal-title":"Semin. Radiat. Oncol."},{"key":"bpexae1039bib5","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.semradonc.2008.04.004","type":"journal-article","article-title":"The linear-quadratic model is an appropriate methodology for determining isoeffective doses at large doses per fraction","volume":"18","author":"Brenner","year":"2008","journal-title":"Seminars in Radiation Oncology"},{"key":"bpexae1039bib6","doi-asserted-by":"publisher","first-page":"S290","DOI":"10.1016\/j.ijrobp.2014.05.981","type":"journal-article","article-title":"Applicability of the Linear-Quadratic Model to Radiation Therapy at a High Dose per Fraction In Vivo","volume":"90","author":"Fujitani","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"bpexae1039bib7","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1093\/jrr\/rrt138","type":"journal-article","article-title":"Applicability of the linear-quadratic model to single and fractionated radiotherapy schedules: an experimental study","volume":"55","author":"Miyakawa","year":"2013","journal-title":"Journal of Radiation Research"},{"key":"bpexae1039bib8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13014-022-02010-9","type":"journal-article","article-title":"Variability of \u03b1\/\u03b2 ratios for prostate cancer with the fractionation schedule: caution against using the linear-quadratic model for hypofractionated radiotherapy","volume":"17","author":"Cui","year":"2022","journal-title":"Radiation Oncology"},{"key":"bpexae1039bib9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1269\/jrr.11095","type":"journal-article","article-title":"Radiobiological evaluation of the radiation dose as used in high-precision radiotherapy: effect of prolonged delivery time and applicability of the linear-quadratic model","volume":"53","author":"Shibamoto","year":"2012","journal-title":"Journal of Radiation Research"},{"key":"bpexae1039bib10","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1007\/s00066-020-01713-w","type":"journal-article","article-title":"Revisiting the formalism of equivalent uniform dose based on the linear-quadratic and universal survival curve models in high-dose stereotactic body radiotherapy","volume":"197","author":"Chan","year":"2021","journal-title":"Strahlenther Onkol"},{"key":"bpexae1039bib11","doi-asserted-by":"publisher","first-page":"4655","DOI":"10.7150\/jca.33001","type":"journal-article","article-title":"Comparison of three radiobiological models in stereotactic body radiotherapy for non-small cell lung cancer","volume":"10","author":"Lu","year":"2019","journal-title":"Journal of Cancer"},{"key":"bpexae1039bib12","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1259\/0007-1285-62-740-679","type":"journal-article","article-title":"The linear-quadratic formula and progress in fractionated radiotherapy","volume":"62","author":"Fowler","year":"1989","journal-title":"Br. J. Radiol."},{"key":"bpexae1039bib13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.7785\/tcrt.2012.500306","type":"journal-article","article-title":"A comparative analysis of radiobiological models for cell surviving fractions at high doses","volume":"12","author":"Andisheh","year":"2013","journal-title":"Technol. Cancer Res. Treat."},{"key":"bpexae1039bib14","doi-asserted-by":"publisher","DOI":"10.1088\/1361-6560\/acf112","type":"journal-article","article-title":"The dose-related plateau effect of surviving fraction in normal tissue during the ultra-high-dose-rate radiotherapy","volume":"68","author":"Hu","year":"2023","journal-title":"Phys. Med. Biol."},{"key":"bpexae1039bib15","doi-asserted-by":"publisher","first-page":"4825","DOI":"10.1088\/0031-9155\/49\/20\/012","type":"journal-article","article-title":"Extending the linear\u2013quadratic model for large fraction doses pertinent to stereotactic radiotherapy","volume":"49","author":"Guerrero","year":"2004","journal-title":"Phys. Med. Biol."},{"key":"bpexae1039bib16","doi-asserted-by":"publisher","first-page":"L9","DOI":"10.1088\/0031-9155\/50\/10\/l01","type":"journal-article","article-title":"The modified linear-quadratic model of Guerrero and Li can be derived from a mechanistic basis and exhibits linear-quadratic-linear behaviour","volume":"50","author":"Carlone","year":"2005","journal-title":"Phys. Med. Biol."},{"key":"bpexae1039bib17","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.1118\/1.2969065","type":"journal-article","article-title":"Some implications of linear-quadratic-linear radiation dose-response with regard to hypofractionation","volume":"35","author":"Astrahan","year":"2008","journal-title":"Med. Phys."},{"key":"bpexae1039bib18","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.ijrobp.2007.10.059","type":"journal-article","article-title":"Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy","volume":"70","author":"Park","year":"2008","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"year":"1967","author":"Elkind","key":"bpexae1039bib19","type":"book"},{"key":"bpexae1039bib20","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/b978-0-12-396455-7.00014-5","type":"journal-article","article-title":"Mechanistic repair-based pad\u00e9 linear-quadratic model for cell response to radiation damage","author":"Belki\u0107","year":"2013","journal-title":"Adv. Quantum Chem."},{"key":"bpexae1039bib21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2307\/3577839","type":"journal-article","article-title":"How well is the probability of tumor cure after fractionated irradiation described by poisson statistics?","volume":"124","author":"Tucker","year":"1990","journal-title":"Radiat. Res."},{"key":"bpexae1039bib22","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1118\/1.3685447","type":"journal-article","article-title":"The use and QA of biologically related models for treatment planning: short report of the TG-166 of the therapy physics committee of the AAPM","volume":"39","author":"Allen Li","year":"2012","journal-title":"Med. Phys."},{"key":"bpexae1039bib23","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/0360-3016(94)00475-z","type":"journal-article","article-title":"Radiation dose-response of human tumors","volume":"32","author":"Okunieff","year":"1995","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"bpexae1039bib24","first-page":"1100","type":"journal-article","article-title":"A unified model of tissue response to radiation","volume":"26","author":"Niemierko","year":"1999","journal-title":"Med. Phys."},{"key":"bpexae1039bib25","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/s0360-3016(01)02585-8","type":"journal-article","article-title":"Optimization of intensity-modulated radiotherapy plans based on the equivalent uniform dose","volume":"52","author":"Wu","year":"2002","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"bpexae1039bib26","doi-asserted-by":"publisher","first-page":"252","DOI":"10.2307\/3576798","type":"journal-article","article-title":"Lethal and potentially lethal lesions induced by radiation --- a unified repair model","volume":"106","author":"Curtis","year":"1986","journal-title":"Radiat. Res."},{"key":"bpexae1039bib27","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/0360-3016(93)90350-5","type":"journal-article","article-title":"Radiobiological studies of PC-3 and DU-145 human prostate cancer cells: x-ray sensitivity in vitro and hypoxic fractions of xenografted tumors in vivo","volume":"25","author":"Leith","year":"1993","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"bpexae1039bib28","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/0167-8140(89)90097-2","type":"journal-article","article-title":"Radio sensitivity of human prostate cancer and malignant melanoma cell lines","volume":"15","author":"Wollin","year":"1989","journal-title":"Radiother. Oncol."},{"key":"bpexae1039bib29","doi-asserted-by":"publisher","first-page":"963","DOI":"10.3109\/0284186X.2012.719635","type":"journal-article","article-title":"Prostate alpha\/beta revisited\u2014an analysis of clinical results from 14168 patients","volume":"51","author":"Dasu","year":"2012","journal-title":"Acta Oncol."},{"key":"bpexae1039bib30","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/s0360-3016(98)00438-6","type":"journal-article","article-title":"Fractionation and protraction for radiotherapy of prostate carcinoma","volume":"43","author":"Brenner","year":"1999","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"bpexae1039bib31","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1088\/0031-9155\/51\/11\/009","type":"journal-article","article-title":"Fitting the linear\u2013quadratic model to detailed data sets for different dose ranges","volume":"51","author":"Garcia","year":"2006","journal-title":"Phys. Med. Biol."},{"key":"bpexae1039bib32","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/s0022-5347(01)63990-9","type":"journal-article","article-title":"Sensitivity of human prostatic carcinoma cell lines to low dose rate radiation exposure","volume":"159","author":"Deweese","year":"1998","journal-title":"The Journal of Urology"},{"key":"bpexae1039bib33","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/s0360-3016(01)01607-8","type":"journal-article","article-title":"Is \u03b1\/\u03b2 for prostate tumors really low?","volume":"50","author":"Fowler","year":"2001","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"bpexae1039bib34","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/s0360-3016(01)02664-5","type":"journal-article","article-title":"Direct evidence that prostate tumors show high sensitivity to fractionation (low \u03b1\/\u03b2 ratio), similar to late-responding normal tissue","volume":"52","author":"Brenner","year":"2002","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"bpexae1039bib35","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.ijrobp.2004.06.204","type":"journal-article","article-title":"New data on the value of \u03b1\/\u03b2\u2014evidence mounts that it is low","volume":"60","author":"Chappell","year":"2004","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"bpexae1039bib36","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.ijrobp.2004.07.723","type":"journal-article","article-title":"Dose\u2013response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy","volume":"61","author":"Cheung","year":"2005","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"bpexae1039bib37","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/s0959-8049(05)80139-x","type":"journal-article","article-title":"The effect of differing radiotherapeutic schedules on the response of glottic carcinoma of the larynx","volume":"29A","author":"Robertson","year":"1993","journal-title":"Eur. J. Cancer"},{"key":"bpexae1039bib38","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/0360-3016(91)90228-v","type":"journal-article","article-title":"Clinical radiobiology of squamous cell carcinoma of the oropharynx","volume":"20","author":"Bentzenh","year":"1991","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"bpexae1039bib39","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/s0167-8140(99)00042-0","type":"journal-article","article-title":"Fractionation sensitivities and dose-control relations of head and neck carcinomas: analysis of the randomized hyperfractionation trials","volume":"51","author":"Stuschke","year":"1999","journal-title":"Radiother. Oncol."},{"key":"bpexae1039bib40","doi-asserted-by":"publisher","first-page":"566","DOI":"10.3390\/cancers4020566","type":"journal-article","article-title":"An estimation of radiobiological parameters for head-and-neck cancer cells and the clinical implications","volume":"4","author":"Qi","year":"2012","journal-title":"Cancers"},{"key":"bpexae1039bib41","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/s0360-3016(97)00561-0","type":"journal-article","article-title":"Effects of keratinocyte growth factor on the proliferation and radiation survival of human squamous cell carcinoma cell lines In Vitro and In Vivo","volume":"40","author":"Ning","year":"1998","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"bpexae1039bib42","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/0360-3016(89)90503-8","type":"journal-article","article-title":"Dose fractionation and regeneration in radiotherapy for cancer of the oral cavity and oropharynx: tumor dose-response and repopulation","volume":"16","author":"Maciejewski","year":"1989","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"bpexae1039bib43","doi-asserted-by":"publisher","first-page":"e543","DOI":"10.1016\/j.clon.2021.08.010","type":"journal-article","article-title":"Moderately hypofractionated radiotherapy and androgen deprivation therapy for high-risk localised prostate cancer: predictors of long-term biochemical control and toxicity","volume":"33","author":"Maulik","year":"2021","journal-title":"Clin. Oncol."},{"key":"bpexae1039bib44","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1016\/j.ijrobp.2023.08.027","type":"journal-article","article-title":"5-year outcomes from PACE B: an international phase III randomized controlled trial comparing stereotactic body radiotherapy (SBRT) vs. conventionally fractionated or moderately hypo fractionated external beam radiotherapy for localized prostate cancer","volume":"117","author":"van As","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"bpexae1039bib45","doi-asserted-by":"publisher","first-page":"100806","DOI":"10.1101\/2024.03.05.24303777","type":"journal-article","article-title":"Re-irradiation to the prostate using stereotactic body radiotherapy (SBRT) after initial definitive radiotherapy: a systematic review and meta-analysis of recent trials","volume":"48","author":"Schr\u00f6der","year":"2024","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"bpexae1039bib46","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00411-024-01078-z","type":"journal-article","article-title":"Stereotactic body radiation therapy for prostate cancer: a dosimetric comparison of IMRT and VMAT using flattening filter and flattening filter-free beams","volume":"63","author":"El-Sayed","year":"2024","journal-title":"Radiat. Environ. Biophys."},{"key":"bpexae1039bib47","doi-asserted-by":"publisher","first-page":"363\u2013","DOI":"10.1200\/JCO.2023.41.6_suppl.363","type":"journal-article","article-title":"Biochemical disease control outcomes of stereotactic body radiation therapy (SBRT) or moderate hypo-fractionation (HFRT) for low- and intermediate-risk prostate cancer (PrCa): retrospective analysis of 12 years of experience at two Canadian cancer centers","volume":"41","author":"Hu","year":"2023","journal-title":"JCO"},{"key":"bpexae1039bib48","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.euo.2018.06.013","type":"journal-article","article-title":"Phase 2 multicenter trial of heterogeneous-dosing stereotactic body radiotherapy for low- and intermediate-risk prostate cancer: 5-year outcomes","volume":"1","author":"Fuller","year":"2018","journal-title":"Eur Urol Oncol."},{"key":"bpexae1039bib49","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.779182","type":"journal-article","article-title":"Dose-intensified stereotactic ablative radiation for localized prostate cancer","volume":"12","author":"Chen","year":"2022","journal-title":"Front. Oncol."},{"key":"bpexae1039bib50","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.radonc.2019.03.002","type":"journal-article","article-title":"Two StereoTactic ablative radiotherapy treatments for localized prostate cancer (2STAR): results from a prospective clinical trial","volume":"135","author":"Alayed","year":"2019","journal-title":"Radiother. Oncol."},{"key":"bpexae1039bib51","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1001\/jamaoncol.2021.0039","type":"journal-article","article-title":"Safety and efficacy of virtual prostatectomy with single-dose radiotherapy in patients with intermediate-risk prostate cancer: results from the PROSINT phase 2 randomized clinical trial","volume":"7","author":"Greco","year":"2021","journal-title":"JAMA Oncol."},{"year":"2024","author":"The Royal College of Radiologists (RCR)","key":"bpexae1039bib52","type":"other"},{"key":"bpexae1039bib53","doi-asserted-by":"publisher","first-page":"5010","DOI":"10.3390\/cancers15205010","type":"journal-article","article-title":"The evolving role of stereotactic body radiation therapy for head and neck cancer: where do we stand?","volume":"15","author":"Mohamad","year":"2023","journal-title":"Cancers"},{"key":"bpexae1039bib54","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.3390\/jcm13113020","type":"journal-article","article-title":"Stereotactic body radiotherapy in recurrent and oligometastatic head and neck tumours","volume":"13","author":"Tham","year":"2024","journal-title":"J. Clin. Med."},{"key":"bpexae1039bib55","doi-asserted-by":"publisher","first-page":"222","DOI":"10.4103\/jmp.jmp_36_17","type":"journal-article","article-title":"A unified dose response relationship to predict high dose fractionation response in the lung cancer stereotactic body radiation therapy","volume":"42","author":"Kehwar","year":"2017","journal-title":"Journal of Medical Physics"},{"key":"bpexae1039bib56","doi-asserted-by":"publisher","first-page":"e290","DOI":"10.1097\/MD.0000000000000290","type":"journal-article","volume":"93","author":"Lee","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"bpexae1039bib57","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.prnil.2015.02.003","type":"journal-article","article-title":"Prostate-specific antigen kinetics after primary stereotactic body radiation therapy using CyberKnife for localized prostate cancer","volume":"3","author":"Park","year":"2015","journal-title":"Prostate Int"},{"key":"bpexae1039bib58","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1186\/s12885-023-10807-4","type":"journal-article","article-title":"A phase 2 study of stereotactic body radiation therapy for squamous cell carcinoma of the head and neck (SHINE): a single arm clinical trial protocol","volume":"23","author":"Lee","year":"2023","journal-title":"BMC Cancer"},{"key":"bpexae1039bib59","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2020.11.013","type":"journal-article","article-title":"Stereotactic radiation therapy for de novo head and neck cancers: a systematic review and meta-analysis","volume":"6","author":"Malik","year":"2021","journal-title":"Adv. Radiat. Oncol."},{"key":"bpexae1039bib60","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s00520-014-2421-y","type":"journal-article","article-title":"Role of stereotactic body radiotherapy for symptom control in head and neck cancer patients","volume":"23","author":"Khan","year":"2014","journal-title":"Support Care Cancer"},{"key":"bpexae1039bib61","doi-asserted-by":"publisher","first-page":"222","DOI":"10.4103\/jmp.JMP_36_17","type":"journal-article","article-title":"A unified dose response relationship to predict high dose fractionation response in the lung cancer stereotactic body radiation therapy","volume":"42","author":"Kehwar","year":"2017","journal-title":"J. Med. Phys."}],"container-title":["Biomedical Physics &amp; Engineering Express"],"original-title":[],"link":[{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/2057-1976\/ae1039","content-type":"text\/html","content-version":"am","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/2057-1976\/ae1039\/pdf","content-type":"application\/pdf","content-version":"am","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/2057-1976\/ae1039","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/2057-1976\/ae1039\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/2057-1976\/ae1039\/pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/2057-1976\/ae1039\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/2057-1976\/ae1039\/pdf","content-type":"application\/pdf","content-version":"am","intended-application":"similarity-checking"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/2057-1976\/ae1039\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:10:53Z","timestamp":1762841453000},"score":1,"resource":{"primary":{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/2057-1976\/ae1039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":61,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,11,10]]},"published-print":{"date-parts":[[2025,11,28]]}},"URL":"https:\/\/doi.org\/10.1088\/2057-1976\/ae1039","relation":{},"ISSN":["2057-1976"],"issn-type":[{"type":"electronic","value":"2057-1976"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"Unveiling the impact of modified cell death models on hypofractionated radiation therapy efficacy","name":"article_title","label":"Article Title"},{"value":"Biomedical Physics & Engineering Express","name":"journal_title","label":"Journal Title"},{"value":"paper","name":"article_type","label":"Article Type"},{"value":"\u00a9 2025 IOP Publishing Ltd. All rights, including for text and data mining, AI training, and similar technologies, are reserved.","name":"copyright_information","label":"Copyright Information"},{"value":"2025-05-05","name":"date_received","label":"Date Received","group":{"name":"publication_dates","label":"Publication dates"}},{"value":"2025-10-07","name":"date_accepted","label":"Date Accepted","group":{"name":"publication_dates","label":"Publication dates"}},{"value":"2025-11-10","name":"date_epub","label":"Online publication date","group":{"name":"publication_dates","label":"Publication dates"}}]}}